

Hematopoietic progenitor kinase 1 inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/H66867300A01EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: H66867300A01EN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Hematopoietic progenitor kinase 1 inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Hematopoietic progenitor kinase 1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Hematopoietic progenitor kinase 1 inhibitors Understanding

Hematopoietic progenitor kinase 1 inhibitors: Overview

Hematopoietic progenitor kinase 1 (HPK1) is a protein kinase that reduces the T cell response to tumor cells. Specifically, HPK1 is a negative regulator of T cell receptor (TCR) signaling. Active HPK1 phosphorylates a protein in the TCR complex, flagging it for degradation, and blocking the TCR signaling important for mounting an immune response against tumor cells. By inhibiting HPK1 with a small molecule compound it may be possible to enhance T cell function and antitumor responses.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hematopoietic progenitor kinase 1 inhibitors R&D. The therapies under development are focused on novel approaches for Hematopoietic progenitor kinase 1 inhibitors.

Hematopoietic progenitor kinase 1 inhibitors Emerging Drugs Chapters

This segment of the Hematopoietic progenitor kinase 1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hematopoietic progenitor kinase 1 inhibitors Emerging Drugs

CFI-40241: Treadwell Therapeutics

CFI-402411 is a novel, highly orally available immunomodulatory small molecule inhibitor of HPK1 (Hematopoietic Progenitor Kinase 1), a critical regulator of immune cell activation, antigen presentation, and T cell responses to immunosuppressive factors. CFI-402411 has the potential to be an effective treatment in a wide range of cancers as a monotherapy, and in combination with other agents including checkpoint inhibitors.

BGB-15025: Beigene

BGB-15025 is an investigational hematopoietic progenitor kinase 1 (HPK1) inhibitor discovered and being developed by BeiGene. HPK1 is a key negative feedback regulator of T-cell receptor signaling, which is believed to play a key role in antitumor immune response. In preclinical studies, the inhibition of HPK1 enhanced T-cell activation, which is expected to enhance the anti-tumor activity of anti-PD-1 inhibitors such as BeiGene's tislelizumab.

Further product details are provided in the report.....

Hematopoietic progenitor kinase 1 inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Hematopoietic progenitor kinase 1 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Hematopoietic progenitor kinase 1 inhibitors

There are approx. 6+ key companies which are developing the Hematopoietic progenitor kinase 1 inhibitors. The companies which have their Hematopoietic progenitor kinase 1 inhibitors drug candidates in the most advanced stage, i.e. Phase I/II include, Treadwell Therapeutics.

Phases

DelveInsight's report covers around 6+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Hematopoietic progenitor kinase 1 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hematopoietic progenitor kinase 1 inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I,

preclinical and discovery stage. It also analyses Hematopoietic progenitor kinase 1 inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hematopoietic progenitor kinase 1 inhibitors drugs.

Hematopoietic progenitor kinase 1 inhibitors Report Insights

- Hematopoietic progenitor kinase 1 inhibitors Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Hematopoietic progenitor kinase 1 inhibitors Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

- How many companies are developing Hematopoietic progenitor kinase 1 inhibitors drugs?

How many Hematopoietic progenitor kinase 1 inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hematopoietic progenitor kinase 1 inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hematopoietic progenitor kinase 1 inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Hematopoietic progenitor kinase 1 inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Treadwell Therapeutics

BeiGene

Nimbus Therapeutics

Blueprint Medicines

RAPT Therapeutics

Ryvu Therapeutics

Arvinas

Key Products

CFI-40241

BGB 15025

Research programme: small molecule HPK1 inhibitors

BLU 2069

NMBS 1

Contents

Introduction

Executive Summary

Hematopoietic progenitor kinase 1 inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Hematopoietic progenitor kinase 1 inhibitors – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I and I/II)

Comparative Analysis

CFI-40241: Treadwell Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

- Comparative Analysis
- BLU 2069: Blueprint Medicines
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Inactive Products
 - Comparative Analysis
- Hematopoietic progenitor kinase 1 inhibitors Key Companies
- Hematopoietic progenitor kinase 1 inhibitors Key Products
- Hematopoietic progenitor kinase 1 inhibitors- Unmet Needs
- Hematopoietic progenitor kinase 1 inhibitors- Market Drivers and Barriers
- Hematopoietic progenitor kinase 1 inhibitors- Future Perspectives and Conclusion
- Hematopoietic progenitor kinase 1 inhibitors Analyst Views
- Hematopoietic progenitor kinase 1 inhibitors Key Companies
- Appendix
- Introduction
- Executive Summary
- Hematopoietic progenitor kinase 1 inhibitors: Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Hematopoietic progenitor kinase 1 inhibitors – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
 - Comparative Analysis
- Drug name: Company name
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)

Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Early Stage Products (Phase I and I/II)
Comparative Analysis
CFI-40241: Treadwell Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Pre-clinical and Discovery Stage Products
Comparative Analysis
BLU 2069: Blueprint Medicines
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
Hematopoietic progenitor kinase 1 inhibitors Key Companies
Hematopoietic progenitor kinase 1 inhibitors Key Products
Hematopoietic progenitor kinase 1 inhibitors- Unmet Needs
Hematopoietic progenitor kinase 1 inhibitors- Market Drivers and Barriers
Hematopoietic progenitor kinase 1 inhibitors- Future Perspectives and Conclusion
Hematopoietic progenitor kinase 1 inhibitors Analyst Views
Hematopoietic progenitor kinase 1 inhibitors Key Companies
Appendix

I would like to order

Product name: Hematopoietic progenitor kinase 1 inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/H66867300A01EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H66867300A01EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970